SARS-CoV-2 hijacks p38β/MAPK11 to promote virus replication
This article has been Reviewed by the following groups
Listed in
- Evaluated articles (ScreenIT)
Abstract
SARS-CoV-2, the causative agent of the COVID-19 pandemic, drastically modifies infected cells in an effort to optimize virus replication. Included is the activation of the host p38 mitogen-activated protein kinase (MAPK) pathway, which plays a major role in inflammation and is a central driver of COVID-19 clinical presentations. Inhibition of p38/MAPK activity in SARS-CoV-2-infected cells reduces both cytokine production and viral replication. Here, we combined genetic screening with quantitative phosphoproteomics to better understand interactions between the p38/MAPK pathway and SARS-CoV-2. We found that several components of the p38/MAPK pathway impacted SARS-CoV-2 replication and that p38β is a critical host factor for virus replication, and it prevents activation of the type-I interferon pathway. Quantitative phosphoproteomics uncovered several SARS-CoV-2 nucleocapsid phosphorylation sites near the N-terminus that were sensitive to p38 inhibition. Similar to p38β depletion, mutation of these nucleocapsid residues was associated with reduced virus replication and increased activation of type-I interferon signaling. Taken together, this study reveals a unique proviral function for p38β that is not shared with p38α and supports exploring p38β inhibitor development as a strategy towards developing a new class of COVID-19 therapies.
Importance
SARS-CoV-2 is the causative agent of the COVID-19 pandemic that has claimed millions of lives since its emergence in 2019. SARS-CoV-2 infection of human cells requires the activity of several cellular pathways for successful replication. One such pathway, the p38 mitogen-activated protein kinase (MAPK) pathway, is required for virus replication and disease pathogenesis. Here, we applied systems biology approaches to understand how MAPK pathways benefit SARS-CoV-2 replication to inform the development of novel COVID-19 drug therapies.
Article activity feed
-
-
SciScore for 10.1101/2021.08.20.457146: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis Lysates were probe sonicated on ice 3 × 1s at 50% power, with 5s of rest in between pulses. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Cells were incubated in primary antibody (1:1000 mouse anti-SARS N IC7 antibody, a kind gift from Thomas Moran) in antibody buffer (1% w/v BSA, 0.03% v/v Triton X-100, 0.1% fish gelatin in PBS) overnight at 4C. anti-SARS N IC7suggested: NoneCells were incubated in 1:1000 anti-mouse AlexaFluor488 or anti-mouse AlexaFluor594 (Thermo Fisher Scientific) and 4’,6-diamidino-2-phenylindole counterstain (DAPI, Thermo … SciScore for 10.1101/2021.08.20.457146: (What is this?)
Please note, not all rigor criteria are appropriate for all manuscripts.
Table 1: Rigor
Ethics not detected. Sex as a biological variable not detected. Randomization not detected. Blinding not detected. Power Analysis Lysates were probe sonicated on ice 3 × 1s at 50% power, with 5s of rest in between pulses. Cell Line Authentication not detected. Table 2: Resources
Antibodies Sentences Resources Cells were incubated in primary antibody (1:1000 mouse anti-SARS N IC7 antibody, a kind gift from Thomas Moran) in antibody buffer (1% w/v BSA, 0.03% v/v Triton X-100, 0.1% fish gelatin in PBS) overnight at 4C. anti-SARS N IC7suggested: NoneCells were incubated in 1:1000 anti-mouse AlexaFluor488 or anti-mouse AlexaFluor594 (Thermo Fisher Scientific) and 4’,6-diamidino-2-phenylindole counterstain (DAPI, Thermo Fisher Scientific) in antibody buffer at room temperature for one hour. anti-mousesuggested: NoneExperimental Models: Cell Lines Sentences Resources CCL-185), HEK 293T cells, a human kidney epithelial cell line (HEK 293T/17, ATCC®, CRL-11268), and Vero E6 cells (Vero 76, clone E6, Vero E6, ATCC® CRL-1586), an African Green Monkey kidney epithelial cell line, were authenticated by ATCC. HEK 293Tsuggested: ATCC Cat# CRL-11268G-1, RRID:CVCL_UE07)HEK 293T/17suggested: ATCC Cat# CRL-11268, RRID:CVCL_1926)A monoclonal ACE2-expressing A549 cell line was a kind gift from Brad Rosenberg. A549suggested: NCI-DTP Cat# A549, RRID:CVCL_0023)Virus stocks were grown on Vero E6 cells. Vero E6suggested: RRID:CVCL_XD71)Cell viability assay: 2 × 104 ACE2-A549 cells in a 96-well white-bottom plate were transfected in triplicate with siRNA pools. ACE2-A549suggested: NoneSoftware and Algorithms Sentences Resources For all analyses, samples were injected on a C18 reverse phase column (30 cm x 75 μm (ID)) packed with ReprosilPur 1.9 μm particles). ReprosilPursuggested: NoneProtein abundance samples were fractioned with Field Assymetric Ion Mobility Spectrometry (FAIMS) fractionation with a FAIMS Pro device (Thermo Fisher Scientific). Field Assymetricsuggested: NoneLysates were run on an SDS-PAGE gel with a protein ladder standard (Bio-Rad Laboratories) and transferred to a nitrocellulose membrane (Bio-Rad Laboratories). Bio-Rad Laboratoriessuggested: (Bio-Rad Laboratories, RRID:SCR_008426)Plate was read for luminescence end-point kinetics with a 1s integration on a Cytation 5 Plate Reader using Gen5 software (Biotek Instruments) Gen5suggested: (Gen5, RRID:SCR_017317)GO-term enrichment was performed using Biojupies (Torre et al. 2018) and visualized using ggplot2 (Wickham 2016). Biojupiessuggested: (BioJupies, RRID:SCR_016346)Alignments to viral genomes was performed using bowtie2 (Langmead and Salzberg, 2012). bowtie2suggested: (Bowtie 2, RRID:SCR_016368)Genome coverage (viral gene counts at each nucleotide position) was analyzed using Integrative Genomics Viewer and visualized with ggplot2 (Robinson et al., 2011) ggplot2suggested: (ggplot2, RRID:SCR_014601)Genome schematic was created with BioRender (BioRender.com) BioRendersuggested: (Biorender, RRID:SCR_018361)Spectronaut reports were analyzed by the MSstats package in the Rstudio statistical programming environment (Bruderer et al., 2017). MSstatssuggested: (MSstats, RRID:SCR_014353)Rstudiosuggested: (RStudio, RRID:SCR_000432)Distances were calculated based on Euclidian distance using the dist function in R and the data were hierarchically ordered using the hclust function in R. hclustsuggested: (HCLUST, RRID:SCR_009154)Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).
Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:One limitation of this approach is that it cannot determine whether the substrates identified were direct substrates of the kinase of interest. SARS-CoV-2 N contains p38-dependent phosphosites: Throughout the viral life cycle, coronavirus nucleocapsid protein (N) performs many crucial functions including oligomerizing along the length of viral RNA for protection, enhancing viral polymerase activity, modulating template switching, and innate immunity evasion (Chang et al., 2014). Post-translational modifications on N have been documented to affect N activities. Phosphorylation of avian Gammacoronavirus infectious bronchitis virus N has been shown to increase the affinity of N for viral RNA compared to non-viral RNA (Chen et al., 2005). Additionally, phosphorylation of Betacoronavirus murine hepatitis virus (MHV) N by GSK-3 has been shown to regulate replication of genomic RNA versus subgenomic RNA by promoting template read-through (Wu et al., 2014). In this study, we identified phosphosites on SARS-CoV-2 N that were p38-dependent, although their fold-changes were more modest compared to that of host p38 substrates that were quantified. As N phosphorylation is known to affect its activity, it is plausible that p38-dependent N phosphorylation is responsible for the phenotypes we observed, but we cannot exclude the possibility that p38-dependent phosphorylation of a host protein may drive these phenotypes. Further experiments are required to determine the impact of novel p38ß ph...
Results from TrialIdentifier: No clinical trial numbers were referenced.
Results from Barzooka: We did not find any issues relating to the usage of bar graphs.
Results from JetFighter: We did not find any issues relating to colormaps.
Results from rtransparent:- Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
- Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
- No protocol registration statement was detected.
Results from scite Reference Check: We found no unreliable references.
-